This study examines how well a new drug, JNJ-95475939, helps people with moderate to severe atopic dermatitis (AD), a chronic skin condition causing itchy, inflamed skin. It compares the drug to a placebo, a harmless pill with no active medicine, to see if the drug is effective. Participants should have had AD symptoms for at least a year before the study starts, and their condition must be quite severe, with a high score on tests measuring eczema and itching. They should have tried other treatments without success.
- The study involves regular visits to the clinic for monitoring.
- Participants should not be pregnant or breastfeeding.
- Potential risks include reactions if they have certain skin or health conditions.
Participants should not have other active skin diseases or infections that could interfere with the study. Also, they cannot have had major surgery recently. This study will help understand if JNJ-95475939 could be a new treatment option for those who haven't found relief with other therapies.